Cargando…

Myelotoxicity of Temozolomide Treatment in Patients with Glioblastoma Is It Time for a More Mechanistic Approach?

Detalles Bibliográficos
Autores principales:	Said, Medhat M., Broen, Martinus P. G., Swart, Eleonora L., Bartelink, Imke H., Kouwenhoven, Mathilde C. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000921/ https://www.ncbi.nlm.nih.gov/pubmed/36900352 http://dx.doi.org/10.3390/cancers15051561

Ejemplares similares

Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825
por: Scheurer, Michael E, et al.
Publicado: (2022)

Assessment of myelotoxicity caused by environmental chemicals.
por: Boorman, G A, et al.
Publicado: (1982)

Analytical approaches to the study of the disposition of myelotoxic agents.
por: Rickert, D E, et al.
Publicado: (1981)

Stem cell assays in the evaluation of myelotoxicity
por: Mangalik, Aroop, et al.
Publicado: (1981)

Evaluation of Myelotoxicity in Dietary Restricted Rats
por: Miyata, Hiroto, et al.
Publicado: (2009)

Cardio-Oncology: Time to Get More Mechanistic
por: Moslehi, Javid, et al.
Publicado: (2017)

Azathioprine-induced Myelotoxicity After Switching Mesalazine Compound
por: Barnhoorn, Marieke C, et al.
Publicado: (2021)

Genetic differences in susceptibility to chemically induced myelotoxicity and leukemia.
por: Nebert, D W
Publicado: (1981)

Azathioprine: Tuberculous perihepatic abscess and myelotoxicity: case report
Publicado: (2021)

Prevention of benzene-induced myelotoxicity by nonsteroidal anti-inflammatory drugs.
por: Kalf, G F, et al.
Publicado: (1989)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Importance of Starting Age for Myelotoxicity Study in Dietary Restricted Rats
por: Asanuma, Fumiko, et al.
Publicado: (2009)

Evaluation of Short-term Myelotoxicity Study in Dietary Reduced Rats
por: Asanuma, Fumiko, et al.
Publicado: (2010)

Combined Effects of Doxorubicin and Temozolomide in Cultured Glioblastoma Cells
por: BALOI, CARINA, et al.
Publicado: (2022)

The frequency of hepatotoxicity and myelotoxicity in leukemic children with different high doses of methotrexate
por: Özdemir, Zeynep Canan, et al.
Publicado: (2016)

Aqueous extract of Phragmitis rhizoma ameliorates myelotoxicity of docetaxel in vitro and in vivo
por: Kim, Jinhee, et al.
Publicado: (2017)

Chlorella sorokiniana Extract Prevents Cisplatin-Induced Myelotoxicity In Vitro and In Vivo
por: Lin, Shyh-Horng, et al.
Publicado: (2020)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Strategies of temozolomide in future glioblastoma treatment
por: Lee, Chooi Yeng
Publicado: (2017)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide
por: Ma, Jun, et al.
Publicado: (2023)

Polymer–Temozolomide Conjugates as Therapeutics for Treating Glioblastoma
por: Ward, Sarah M., et al.
Publicado: (2018)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

Dovitinib enhances temozolomide efficacy in glioblastoma cells
por: Thanasupawat, Thatchawan, et al.
Publicado: (2017)

Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice.
por: Morelli, D., et al.
Publicado: (1997)

NICE verdict on Temozolomide: where next?
por: Brada, M
Publicado: (2002)

Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose
por: Yin, Dandan, et al.
Publicado: (2017)

Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma
por: Fresnais, Margaux, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19
por: Baalbaki, Nadia, et al.
Publicado: (2023)

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
por: JIAPAER, Shabierjiang, et al.
Publicado: (2018)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
por: Herbener, Verena J., et al.
Publicado: (2020)

Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma
por: Kim, Hyungsin, et al.
Publicado: (2019)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

Predicted expression of genes involved in the thiopurine metabolic pathway and azathioprine discontinuation due to myelotoxicity
por: Daniel, Laura L., et al.
Publicado: (2022)

Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report
por: Schreiber, Stefanie, et al.
Publicado: (2010)

Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells
por: Beltzig, Lea, et al.
Publicado: (2022)

Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide
por: Sun, Stella, et al.
Publicado: (2012)

Glucose Influences the Response of Glioblastoma Cells to Temozolomide and Dexamethasone
por: Bielecka-Wajdman, Anna M, et al.
Publicado: (2022)

Diurnal expression of MRP4 in bone marrow cells underlies the dosing-time dependent changes in the oxaliplatin-induced myelotoxicity
por: Kato, Mizuki, et al.
Publicado: (2020)

Effects of varying the interval between courses of methotrexate on its myelotoxic and anti-leukaemic activities.
por: Harding, B., et al.
Publicado: (1977)

Cannot write session to /tmp/vufind_sessions/sess_gsg08d1og8os7uck3jq67pd3me